- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- FT836, Cetuximab, Trastuzumab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 9
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more
- Conditions
- Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nab-paclitaxel, Paclitaxel, Questionnaire Administration, Ramucirumab
- Procedure · Other · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Interventions
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
- Drug · Biological · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
- Interventions
- SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
- Conditions
- Neoplasms, Benign, Neoplasms, Malignant
- Interventions
- OxyChip
- Device
- Lead sponsor
- Periannan Kuppusamy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
- Interventions
- Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Biospecimen Collection, Cytarabine, Lumbar Puncture, Methotrexate, Therapeutic Hydrocortisone
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
- Conditions
- Unresectable Locally Advanced Pancreatic Carcinoma
- Interventions
- OncoSil™
- Device
- Lead sponsor
- OncoSil Medical Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 1 more
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Interventions
- LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
- Interventions
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Stanford, California • Athens, Georgia + 5 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 38
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, LY2181308 sodium, Prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
- Interventions
- NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
- Device · Radiation · Drug
- Lead sponsor
- Jonathan Schoenfeld, MD, MPH
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Psilocybin, Neuropathy
- Interventions
- Psilocybin (drug), Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- NIS793, Spartalizumab, gemcitabine, nab-paclitaxel
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
- Procedure · Drug · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Rectal Neoplasms
- Interventions
- 5FU/Leucovorin
- Drug
- Lead sponsor
- Marks, John, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Triple Negative Breast Cancer
- Interventions
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Biological · Device · Other
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 46
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Triple-Negative Breast Carcinoma
- Interventions
- Biopsy of Breast, Biospecimen Collection, Breast Surgery, Chemotherapy, Computed Tomography, Contrast Enhanced Digital Mammography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration, Tissue Collection, Ultrasound Imaging
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor, Metastatic Testicular Seminoma, Stage II Testicular Cancer AJCC v8, Stage III Testicular Cancer AJCC v8
- Interventions
- Audiometric Test, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Sodium Thiosulfate Anhydrous
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more